臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 50703001 在线人数 : 323 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"orlando m"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 1-10 / 29 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-08-19T00:20:46Z	Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review	Lim H.Y.; Kim J.S.; Orlando M.; Chen L.-T.; Chen J.-S.; CHIUN HSU; Oh D.-Y.; Park J.O.
臺大學術典藏	2021-04-23T05:56:33Z	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis	Chih-Hsin Yang;Cheng Y.;Murakami H.;Yang P.-C.;He J.;Nakagawa K.;Kang J.H.;Kim J.-H.;Hozak R.R.;Nguyen T.S.;Zhang W.L.;Enatsu S.;Puri T.;Orlando M.; CHIH-HSIN YANG; Cheng Y.; Murakami H.; Yang P.-C.; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M.
臺大學術典藏	2021-03-09T06:46:04Z	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in East Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trial	Urba S.; RUEY-LONG HONG; Hossain A.M.; Cheng R.; Orlando M.
臺大學術典藏	2021-01-28T01:06:25Z	Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review	Chen L.-T.;Oh D.-Y.;Ryu M.-H.;Kun-Huei Yeh;Yeo W.;Carlesi R.;Cheng R.;Kim J.;Orlando M.;Kang Y.-K.; Chen L.-T.; Oh D.-Y.; Ryu M.-H.; KUN-HUEI YEH; Yeo W.; Carlesi R.; Cheng R.; Kim J.; Orlando M.; Kang Y.-K.
臺大學術典藏	2020-12-02T02:33:19Z	Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations	Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al.
臺大學術典藏	2020-12-02T02:33:06Z	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis	Yang J.C.-H.; PAN-CHYR YANG et al.; Yang J.C.-H.; Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M.
臺大學術典藏	2020-08-13T06:33:40Z	East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL)	Orlando M.; Puri T.; Alexandris E.; Lee P.; Zimmermann A.H.; Cho E.K.; Kang J.-H.; JIN-YUAN SHIH; Kim J.-H.; Park K.
臺大學術典藏	2020-08-13T06:33:32Z	Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials	Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C.
臺大學術典藏	2020-05-26T09:27:18Z	Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in east asian patients with advanced non-small cell lung cancer: Results of an exploratory subgroup analysis of a phase III trial	Chih-Hsin Yang;Simms L;Park K;Lee J.S;Scagliotti G;Orlando M.; CHIH-HSIN YANG; Simms L; Park K; Lee J.S; Scagliotti G; Orlando M.
臺大學術典藏	2020-05-26T09:27:06Z	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer	Orlando M.;Linn C;Peng G;Blair J.M;Chen Y.-M;Xiu Q;Kang J.-H;Liang J;Chih-Hsin Yang;Ahn M.-J; Ahn M.-J; CHIH-HSIN YANG; Liang J; Kang J.-H; Xiu Q; Chen Y.-M; Blair J.M; Peng G; Linn C; Orlando M.

显示项目 1-10 / 29 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目